Sure, you’ve used claims and electronic health records in your research. But have you ever explored linking phenotypic and genomic or other -omic data to assess the full view of the patient journey? In this fireside chat with experts from Optum Life Sciences and DNAnexus, learn how longitudinal, linked data sets enable life sciences companies to discover new druggable targets, identify potential treatment populations, understand the genetic testing landscape and barriers to access, and more. We’ll aim to:
John Ellithorpe, Ph.D., has spent his career driving innovative technology to improve people's lives. At DNAnexus, John leads the Product, Engineering, Science, Services, and Support teams. Prior, John was CPO at Vantiq, delivering intelligent systems in the IoT space, and co-founder, CTO, and CPO at Model N (NYSE: MODN) where he led the Global Products group and drove technical strategy. John holds a Bachelor of Science in Physics from the University of California at Irvine and a Ph.D. in Physics from the Massachusetts Institute of Technology.
Ashley Brenton, Ph.D. is the Vice President of Real-World Evidence and Genomics for Optum Life Sciences. She is responsible for leading the data strategy, development, business development, and operations for real-world data with a focus on genomics. In this role, she bridges the gap between clinical genomics and product development to leverage the wealth of Optum data into commercial datasets and strategic alliances. Prior to joining Optum, Dr. Brenton was the chief science officer at Mycroft Bioanalytics where she led corporate valuation and sales strategy of the intellectual property portfolio, including the world’s largest clinicogenomic biobank in chronic pain. Previously, Dr. Brenton developed and commercialized a number of precision medicine tests and algorithms while building clinicogenomic datasets. In addition to her product development in the space, she has established herself as a thought leader, publishing a number of manuscripts that provide support for the integration of clinicogenomics in healthcare. Before entering the industry, Dr. Brenton was a molecular biologist in academia, earning a bachelor’s degree in Public Health Studies from Johns Hopkins, a Ph.D. from the University of California Davis, and a viral pathogenesis fellowship from the Scripps Research Institute.
Matthew Andreatta, Ph.D., serves as a Solutions Science Director for DNAnexus helping Diagnostic companies, Pharmaceutical partners, and Data Providers glean actionable insights from multiomic and clinical information. He’s spent the last 9 years building tools and visualizations to explore health-related genomic datasets that support patient-driven decisions and analytic workflows. Matthew holds a Bachelor of Science in Biotechnology from University of California at Davis, a Master’s of Science in Molecular Biology from Purdue University, and a Ph.D. in Genomics from Purdue University.
Eze serves as Vice President of New Products and Partnerships for Optum Life Sciences. He has acquired nearly 17 years of experience supporting the life sciences with data, analytics and consulting solutions that enable and support drug discovery, R&D, and clinical trial optimization, as well as the market access and commercial workflows. He has held various roles of increased responsibility with organizations such as IQVIA, Clarivate/DRG, and OptimizeRx. Eze received his Bachelor’s of Science from Union College (NY) and a Master’s in Business from Harvard University.